Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.

In this study, researchers found that combining topical 5% minoxidil with intradermal triamcinolone microinjections significantly improved hair density in women with androgenetic alopecia compared to minoxidil alone. However, further research is necessary to confirm these findings in a larger population.

In this study, among 2,000 patients with alopecia universalis, mesotherapy combined with systemic treatments like BMI, JAK inhibitors, and adalimumab showed the highest success in hair regrowth, particularly for children, with the combination therapy group achieving a 42% positive response rate.

This study established a novel in vivo "whisker follicle microinjection assay" using mouse whiskers to evaluate hair growth and pigmentation effects of various chemicals and proteins, identifying minoxidil, ruxolitinib, and RSPO1 as growth promoters, while deoxyarbutin inhibited pigmentation and Nbl1 emerged as a growth inhibitor.

This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.

This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.

This study found that mesotherapy combined with minoxidil for androgenetic alopecia shows promise with high patient satisfaction and manageable risks, though some uncommon side effects may occur.

This review discusses the lack of adequate clinical trials evaluating the efficacy and safety of mesotherapy for cosmetic hair loss and reports no new results.

This study found that in mice with alopecia areata, a single subcutaneous injection of botulinum neurotoxin serotype A significantly reduced hair loss and stimulated hair follicle regeneration.

This study found that Botox® was most effective at a 25 U/ml concentration, while Dysport® and Neurobloc® were optimal at 100 U/ml for producing anhidrotic areas after injections.

In this case study, a patient with long-standing androgenic alopecia and lupus showed a satisfactory response to treatment with oral and topical minoxidil after suboptimal outcomes with previous treatments.

This review highlights the promising potential of mesotherapy for delivering dutasteride and minoxidil as treatments for androgenetic alopecia, emphasizing the need for more research on drug preparation, delivery, and maintenance to establish its safety and effectiveness.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

In this study, Hedgehog signaling in dermal papilla fibroblasts was found to accelerate hair growth and induce follicle multiplication in mice via the SCUBE3/TGF-β pathway, with some effects observed in human scalp hair follicles.

This review highlights the use of microneedling devices and patches to deliver cosmetic agents through the skin, noting their applications in skin rejuvenation and safety considerations such as potential skin irritation and infection.

This study reviewed existing literature on mesotherapy and developed evidence-based guidelines, which support its standardized and safe use for osteoarticular pain, rehabilitation, and dermatology, marking a shift from practice based on personal beliefs to an evidence-based approach.

This review discusses various treatments for noncicatricial alopecias, such as androgenetic alopecia and alopecia areata, including mesotherapy, microneedling, and platelet-rich plasma therapy, noting that outcomes vary across these procedures.

In this study, researchers observed that knocking down the LPA 4 receptor in zebrafish embryos led to vascular and lymph vessel development abnormalities, including edema and decreased heartbeats.

This case report highlights two instances of patchy alopecia occurring after mesotherapy with dutasteride, illustrating a possible paradoxical side effect of this treatment for androgenetic alopecia.

This review discusses various methods for delivering CRISPR/Cas9 for gene editing in vitro and in vivo, highlighting delivery as a major challenge but reports no new experimental results.

This study found that subcutaneous administration of Botulinum toxin type A significantly reduced histamine-induced itch intensity and neurogenic inflammation in human skin compared to saline.

This study found that dutasteride mesotherapy increased the diameter of existing hair in five Mexican men with androgenetic alopecia, without reported side effects.

This study found that microbotox, especially when injected intradermally, effectively reduces enlarged facial pores with higher patient satisfaction and longer-lasting results compared to its topical application after microneedling.

This article introduces a needleless microjet injector using laser pulse energy for tattoo pigments in scalp micropigmentation, highlighting an almost painless procedure without anesthesia.

This literature review conducted a comprehensive analysis of existing studies on micro-needling mesotherapy in dermatology and aims to offer a practical guide for its clinical application, though it provides no new experimental findings.

This review discusses micro needling as a therapeutic option for various dermatological conditions, such as scars and pigmentation, and reports no new clinical results; the authors note potential side effects and contraindications.

A 2 mm needle is effective and precise for skin injections.

This article discusses the potential of novel microneedle transdermal systems for enhanced drug and vaccine delivery through the skin, but reports no clinical results and emphasizes ongoing trials.

This study reviews the evolution and modifications of microneedle drug delivery systems, initially designed for percutaneous use, now expanded for targeting a variety of tissues and organs such as ocular, oral mucosal, and gastrointestinal, suggesting widespread future applicability.